620 related articles for article (PubMed ID: 9722075)
1. Acute graft-versus-host disease after bone marrow transplantation with a single HLA-DPB1*1001 mismatch: involvement of different TCRBV subsets.
Gaschet J; Gallot G; Ibisch C; Lim A; Even J; Vivien R; Hallet MM; Milpied N; Vié H
Bone Marrow Transplant; 1998 Aug; 22(4):385-92. PubMed ID: 9722075
[TBL] [Abstract][Full Text] [Related]
2. Acute graft versus host disease due to T lymphocytes recognizing a single HLA-DPB1*0501 mismatch.
Gaschet J; Lim A; Liem L; Vivien R; Hallet MM; Harousseau JL; Even J; Goulmy E; Bonneville M; Milpied N; Vié H
J Clin Invest; 1996 Jul; 98(1):100-7. PubMed ID: 8690780
[TBL] [Abstract][Full Text] [Related]
3. Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor.
Morishima Y; Yabe T; Matsuo K; Kashiwase K; Inoko H; Saji H; Yamamoto K; Maruya E; Akatsuka Y; Onizuka M; Sakamaki H; Sao H; Ogawa S; Kato S; Juji T; Sasazuki T; Kodera Y;
Biol Blood Marrow Transplant; 2007 Mar; 13(3):315-28. PubMed ID: 17317585
[TBL] [Abstract][Full Text] [Related]
4. Specificity of T cells invading the skin during acute graft-vs.-host disease after semiallogeneic bone marrow transplantation.
Gaschet J; Mahé B; Milpied N; Devilder MC; Dréno B; Bignon JD; Davodeau F; Hallet MM; Bonneville M; Vié H
J Clin Invest; 1993 Jan; 91(1):12-20. PubMed ID: 8423212
[TBL] [Abstract][Full Text] [Related]
5. DPB1 disparities contribute to severe GVHD and reduced patient survival after unrelated donor bone marrow transplantation.
Loiseau P; Espérou H; Busson M; Sghiri R; Tamouza R; Hilarius M; Raffoux C; Devergie A; Ribaud P; Socié G; Gluckman E; Charron D
Bone Marrow Transplant; 2002 Oct; 30(8):497-502. PubMed ID: 12379888
[TBL] [Abstract][Full Text] [Related]
6. The impact of T-cell depletion on the effects of HLA DR beta 1 and DQ beta allele matching in HLA serologically identical unrelated donor bone marrow transplantation.
Gajewski J; Gjertson D; Cecka M; Tonai R; Przepiorka D; Hunt L; Giralt S; Chan KW; Feig S; Territo M; Andersson B; van Besien K; Khouri I; Fischer H; Babbitt L; Ippolitti C; Schiller G; Lill M; Warkentin D; Neumann J; Petz L; Terasaki P; Champlin R
Biol Blood Marrow Transplant; 1997 Jun; 3(2):76-82. PubMed ID: 9267667
[TBL] [Abstract][Full Text] [Related]
7. Recognition of leukemic blasts by HLA-DPB1-specific cytotoxic T cell clones: a perspective for adjuvant immunotherapy post-bone marrow transplantation.
Ibisch C; Gallot G; Vivien R; Diez E; Jotereau F; Garand R; Vié H
Bone Marrow Transplant; 1999 Jun; 23(11):1153-9. PubMed ID: 10382955
[TBL] [Abstract][Full Text] [Related]
8. HLA-DP and allogeneic bone marrow transplantation.
Moreau P; Cesbron A
Bone Marrow Transplant; 1994 Jun; 13(6):675-81. PubMed ID: 7920290
[TBL] [Abstract][Full Text] [Related]
9. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
[TBL] [Abstract][Full Text] [Related]
10. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
Russell CA
Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
[TBL] [Abstract][Full Text] [Related]
11. The degree of matching at HLA-DPB1 predicts for acute graft-versus-host disease and disease relapse following haematopoietic stem cell transplantation.
Shaw BE; Potter MN; Mayor NP; Pay AL; Smith C; Goldman JM; Prentice HG; Marsh SG; Madrigal JA
Bone Marrow Transplant; 2003 Jun; 31(11):1001-8. PubMed ID: 12774051
[TBL] [Abstract][Full Text] [Related]
12. Distinct TCRAV and TCRBV repertoire and CDR3 sequence of T lymphocytes clonally expanded in blood and GVHD lesions after human allogeneic bone marrow transplantation.
Hirokawa M; Matsutani T; Saitoh H; Ichikawa Y; Kawabata Y; Horiuchi T; Kitabayashi A; Yoshioka T; Tsuruta Y; Suzuki R; Miura AB; Sawada K
Bone Marrow Transplant; 2002 Dec; 30(12):915-23. PubMed ID: 12476285
[TBL] [Abstract][Full Text] [Related]
13. HLA-B44-directed cytotoxic T cells associated with acute graft-versus-host disease following unrelated bone marrow transplantation.
Keever CA; Leong N; Cunningham I; Copelan EA; Avalos BR; Klein J; Kapoor N; Adams PW; Orosz CG; Tutschka PJ
Bone Marrow Transplant; 1994 Jul; 14(1):137-45. PubMed ID: 7951101
[TBL] [Abstract][Full Text] [Related]
14. Helper and cytotoxic T cell precursor frequencies are not predictive for development of acute graft-versus-host disease after partially T cell-depleted HLA-identical sibling BMT.
van der Meer A; Allebes WA; Voorter CE; van den Berg-Loonen EM; Schattenberg AV; de Witte TJ; Joosten I
Bone Marrow Transplant; 1998 Dec; 22(11):1049-55. PubMed ID: 9877266
[TBL] [Abstract][Full Text] [Related]
15. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
[TBL] [Abstract][Full Text] [Related]
16. CTL clones isolated from an HLA-Cw-mismatched bone marrow transplant recipient with acute graft-versus-host disease.
Sugimoto K; Murata M; Terakura S; Naoe T
J Immunol; 2009 Nov; 183(9):5991-8. PubMed ID: 19812210
[TBL] [Abstract][Full Text] [Related]
17. Possible involvement of allogeneic antigens recognised by donor-derived CD4 cytotoxic T cells in selective GVL effects after stem cell transplantation of patients with haematological malignancy.
Matsushita M; Yamazaki R; Ikeda H; Mori T; Sumimoto H; Fujita T; Okamoto S; Ikeda Y; Kawakami Y
Br J Haematol; 2006 Jan; 132(1):56-65. PubMed ID: 16371020
[TBL] [Abstract][Full Text] [Related]
18. The putative role of HLA-C recognition in graft versus host disease (GVHD) and graft rejection after unrelated bone marrow transplantation (BMT).
Bishara A; Amar A; Brautbar C; Condiotti R; Lazarovitz V; Nagler A
Exp Hematol; 1995 Dec; 23(14):1667-75. PubMed ID: 8542963
[TBL] [Abstract][Full Text] [Related]
19. Measurement of recipient-specific alloreactivity: is GVHD predictable?
Theobald M; Bunjes D; Nierle T; Arnold R; Heimpel H
Bone Marrow Transplant; 1993; 12 Suppl 3():S18-23. PubMed ID: 8124251
[TBL] [Abstract][Full Text] [Related]
20. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
